Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Q1 FY22 Earnings Presentation
15 slides from Zydus Lifesciences's earnings presentation, Aug 11, 2021
Slide 1: Cover letter to stock exchanges
_____________________________________________________________________ August 11, 2021 Listing Department Code: 532321 BOMBAY STOCK EXCHANGE LIMITED P J Towers, Dalal Street, Fort, Mumbai-400001 Listing Department Code: CADILAHC NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Co
Slide 2: Investor Presentation Q1FY22
Investor Presentation Q1FY22 11th August, 2021
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF CADILA HEALTHCARE LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general
Slide 4: Consolidated Financial Highlights Q1FY22
Consolidated Financial Highlights Q1FY22 Consolidated Revenue from operations at INR 4,025 Crores, up 15% Y-o-Y and up 9% Revenue Q-o-Q. INR Crores Y-o-Y Q-o-Q Consolidated EBIDTA at INR 933 Crores up 18% Y-o-Y and up 16% Q-o-Q. EBIDTA 4,025 15% 9% margin for Q1’22 is 23.2%, against 22.5% in Q1’
Slide 5: Consolidated Financial Performance Q1 FY22
Consolidated Financial Performance Q1 FY22 Particulars (INR Crores) Q1 FY22 Q4 FY21 Q-o-Q Q1 FY21 Y-o-Y 1. On a Y-o-Y basis, growth in Growth Growth revenues was driven by strong Revenue from operations (Note 1.) 4,025 3,692 9% 3,515 15% growth in India geography Other income 32 -31 204% 23 40% part
Slide 6: Margin Trends
Margin Trends * PBT and PAT Margins are excluding exceptional and one off items. 5
Slide 7: Diversified Business Portfolio Q1 FY22
Diversified Business Portfolio Q1 FY22 Market, Sales Value Q1 21-22 % share in consolidated sales ▲% Growth 6
Slide 8: India Geography: Human health formulations business
India Geography: Human health formulations business INR Crores Highlights Business growth largely driven by base business, COVID portfolio and lower base effect of previous year. Rank improved by 1 position; ranked 4th in the market* Gained market share^ in anti-diabetic, anti-infective and nu
Slide 9: India Geography: Consumer Wellness
India Geography: Consumer Wellness INR Crores Highlights 5 out of 7 brands seen double digit growth. Nutralite brand delivered a strong growth both in institutional and retail segments in Q1’22 despite lockdown in key markets. Complan brand registered a double digit growth in Q1’22; led Y-o-Y
Slide 10: US Formulations Business
US Formulations Business INR Crores Highlights Pricing pressure in some of products and settling of supply issues in US market resulted in limited one time buy opportunities which lead to a sequential de-growth. Despite increased competition US generics business volumes continue to grow. New p
Slide 11: Emerging Markets
Emerging Markets INR Crores Highlights Key emerging market countries grew in double digit despite Doctor - MR physical interaction remained muted in almost all countries. New products launches in Q1’22: Brazil - 5 New products dossiers filling in Q1’22: Y-o-Y ▲17% • 1 with the Brazilian Regula
Slide 12: Innovation - Covid19 updates
Innovation - Covid19 updates Submitted the dossier to DCGI for an EUA of ZyCov-D vaccine with an interim Phase III CTs efficacy data for 2 mg Phase III CTs data for 2 mg dose study of ZyCov-D vaccine also confirmed the safety for children in the age group of 12 to 18 years. Phase III CTs were
Slide 13: Innovation: other updates
Innovation: other updates NCE Biologics In July, 2021, EMA granted Orphan Drug Designation (ODD) to Launched Trastuzumab Emtansine, the first ADC biosimilar Saroglitazar Magnesium for PBC indication; ODD status provides and a highly effective drug for treating both Early and an exclusivity for 1
Slide 14: Glossary
Glossary • Revenue from operations represents Sales and other operating revenues. • Net debt: It is defined as the sum of long-term borrowings, short-term borrowings, minus cash and cash equivalents, current investments, and other bank balances. • EBIDTA: Earnings before interest, depreciation, taxa
Slide 15: Thank you
Thank you 14